Market capitalization | $292.83m |
Enterprise Value | $308.14m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.95 |
P/S ratio (TTM) P/S ratio | 3.75 |
P/B ratio (TTM) P/B ratio | 7.36 |
Revenue growth (TTM) Revenue growth | 24.66% |
Revenue (TTM) Revenue | $78.06m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
2 Analysts have issued a Sanara MedTech Inc forecast:
2 Analysts have issued a Sanara MedTech Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 78 78 |
25%
25%
|
|
Gross Profit | 66 66 |
30%
30%
|
|
EBITDA | -4.04 -4.04 |
17%
17%
|
EBIT (Operating Income) EBIT | -8.45 -8.45 |
0%
0%
|
Net Profit | -8.36 -8.36 |
2%
2%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. It offers CellerateRX Surgical Activated Collagen Adjuvant and HemaQuell Resorbable Bone Hemostat. The company was founded in 1982 and is headquartered in Fort Worth, TX.
Head office | United States |
CEO | Ron Nixon |
Employees | 107 |
Founded | 1982 |
Website | www.sanaramedtech.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.